Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy 5b for High-Risk Myeloma
NCT02128230Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Jun 2014
- Primary completion
- Feb 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by University of Arkansas. Started Jun 2014; status: terminated.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02128230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128230.